Molecular therapeutics is a recognized promising approach for melanoma, but relevant target genes remain elusive. We report that overload of the recently cloned H11/HspB8 induces apoptosis in 55% of examined melanoma cultures. Apoptosis was determined by activation of caspases-9 and -3 and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL), and was not seen in normal melanocytes. It was associated with H11/HspB8 complexation with transforming growth factor-b-activated kinase (TAK) 1 and activation of TAK1 and p38 mitogen activated protein 3 kinases. TAK1 was not bound, nor activated by the H11/HspB8 mutant W51C, which has dominant antiapoptotic activity. b-Catenin was phosphorylated by activated TAK1, inhibiting its nuclear accumulation and mictophthalmiaassociated transcription factor and cyclin dependent kinase 2 expression. The dominant-negative TAK1 mutant K63W inhibited b-catenin phosphorylation and caspase activation. The data indicate that H11/HspB8 overload causes melanoma growth arrest and apoptosis through TAK1 activation and suggest that H11/HspB8 is a promising molecular therapy target.
Introduction
Apoptosis is a tightly regulated irreversible process. It is primarily mediated by cysteine proteases (caspases), which are activated by the cleavage of inactive zymogens (procaspases) in a sequential cascade or by autocatalysis. In the intrinsic cascade, caspase-9 activates caspase-3, which is a main effector of apoptosis and it is responsible for the proteolytic cleavage of proteins required for cell survival (Aurelian, 2005) . Apoptosis is a promising molecular therapy platform for melanoma, an aggressive and resistant cancer with increasing incidence and a growing lifetime risk (Fink et al., 2001; Margolin, 2004; Tsao and Sober, 2005) . However, genes that reconnect the apoptotic cascade in melanoma remain elusive.
Transforming growth factor-b-activated kinase 1 (TAK1) is a member of the MAP3K family. It phosphorylates MKK-3, -4, -6 and -7, thereby activating the proapoptotic c-Jun N-terminal kinase (JNK) and p38MAPK cascades (Davis, 2000) and was implicated in prostate cancer apoptosis (Edlund et al., 2003) . TAK1 also negatively impacts on the transcriptional activity of b-catenin (Ishitani et al., 1999) , which is involved in melanoma development, through its target, Microphthalmia-associated transcription factor (MITF) (Widlund et al., 2002) .
We first cloned the heat shock protein H11/HspB8 by screening an expression library with antibody to 13 residues within the PK fragment of the HSV-2 protein ICP10 (Smith et al., 2000) that also contains a degenerate a-crystallin motif (Chabaud et al., 2003) . H11/HspB8 contains nuclear export sequences, does not translocate to the nucleus upon heat shock, and has protein kinase activity (Chowdary et al., 2004; Gober et al., 2003 Gober et al., , 2005 Hase et al., 2005) . Unlike other family members, which are overexpressed in tumor cells and exert cytoprotective activity (Ciocca and Calderwood, 2005) , H11/HspB8 is silenced in melanoma (Sharma et al., 2006) , where its overload triggers apoptosis (Gober et al., 2003) . The studies described in this report were designed to determine the mechanism of apoptosis induced by H11/HspB8 in melanoma cells.
Results

H11/HspB8 triggers apoptosis in melanoma, but not melanocytes
Because H11/HspB8 DNA is aberrantly methylated/ silenced in 50-60% of melanoma but not melanocytes (Sharma et al., 2006) , we wanted to know whether its upregulation triggers melanoma-specific apoptosis. Seven melanoma lines (SKMEL-2, SKMEL-28, A375, A2058, G361, HT144, SKMEL-31), two freshly isolated melanoma cultures (LM and MR) and two cultures of normal melanocytes (NM1 and NM2) were treated with Aza-C (2 mM) and examined for H11/HspB8 expression and apoptosis. A time-dependent increase in H11/ HspB8 levels was seen in SKMEL-2, SKMEL-28, A2058, A375 and LM cells, but not in normal melanocytes or HEK293 cells (Figure 1a) . Aza-Cinduced H11/HspB8 overload was accompanied by decreased melanoma cell viability (determined by trypan blue exclusion) ( Figure 1c ) and apoptosis (determined by Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) which was blocked by H11/HspB8 antisense oligo deoxynucleotides (aODN), but not sense (sODN) (Figure 1d ). In HEK293 (not melanoma) cells, H11/HspB8 was upregulated by heat shock (Figure 1b ), but it did not induce apoptosis (data not shown). Dox (2 mg/ml) treatment of melanoma cells stably transfected with Tet-regulated H11/HspB8 decreased viability and increased apoptosis (day 3; 70-87% TUNEL þ cells), associated with H11/HspB8 overload ( Figure 2 ). It did not alter the expression of Hsp70 and Hsp27 (Supplementary Figure 1) , suggesting that they are not involved in H11/HspB8 induced apoptosis. Dox had no effect on untransfected cells or cells transfected with the empty vector (Figure 2c ).
Dox-induced H11/HspB8 overload causes caspase activation
Extracts of H11/HspB8-transfected melanoma cultures treated or not with Dox were immunoblotted with antibodies to caspase-9 or -3. The levels of procaspase-9 decreased on day 1 after Dox treatment, concomitant with the appearance of its p35 cleavage product and were followed by decreased levels of procaspase-3 (indicative of activation) (Figure 3a ). Caspase activation was specific for H11/HspB8 overload and was not seen in Dox-treated melanocytes (Figure 3b ). TUNEL Overload of the heat-shock protein B Li et al colocalized with H11/HspB8 overload, as evidenced by double immunofluorescence with fluorescein isothiocyanate (FITC)-dUTP and Texas red-labeled H11/HspB8 antibody (35-41 and 67-78% cells on days 2 and 3 after Dox, respectively) and it was blocked by the pancaspase inhibitor z-VAD-fmk (100 mM) (Figure 3c ). The data indicate that apoptosis is through activation of the intrinsic caspase pathway.
TAK1 is bound and activated by H11/HspB8, but not its apoptosis-negative mutant W51C To examine whether apoptosis is through TAK1 activation, we used reciprocal pull-down assays with H11 and TAK1 antibodies. H11/HspB8 coprecipitated with TAK1 from Dox-treated (1-3 days), but not untreated, melanoma cells and the precipitates contained a slowly migrating band, consistent with activated TAK1 (pTAK1) (Kishimoto et al., 2000) (Figure 4a and b). The slower band is, indeed, pTAK1, because it was also seen in the anti-TAK1 precipitates from Doxtreated [ 32 P]-orthophosphate labeled cells (Figure 4c ). The TAK1-associated protein TAB1 was also in the H11/HspB8 precipitates (Supplementary Figure 2) . TAK1 did not co-precipitate with the dominant antiapoptotic H11/HspB8 mutant W51C, neither from G361 melanoma cells, which naturally express W51C (Gober et al., 2003) , nor from TAG51 cells, which are stably transfected with W51C (Gober et al., 2003) and the precipitates did not contain pTAK1 (Figure 4d and e). Co-precipitation and TAK1 activation were also not seen in HEK293 cells (Figure 4f ), or melanocytes (Figure 4g ), which were negative for apoptosis.
Immunocomplex PK assays with TAK1 antibody and the TAK1 substrate MKK6 (Singhirunnusorn et al., 2005) , indicated that MKK6 was phosphorylated in Overload of the heat-shock protein B Li et al Dox-treated, but not untreated melanoma cells and the precipitates were positive for pTAK1 (Figure 5a ). MKK6 was not phosphorylated in immunocomplex PK assays of G361 (data not shown) or TAG51 (Figure 5b ) cells. Collectively the data indicate that apoptosis caused by H11/HspB8 overload is associated with TAK1 activation.
Dox treatment blocks b-catenin nuclear accumulation
To examine the impact of TAK1 activation on b-catenin (Ishitani et al., 1999) , the nuclear accumulation of which was associated with melanoma cell growth (Widlund et al., 2002; Saito et al., 2003) , H11/HspB8-transfected melanoma cells were treated, or not, with Dox (1-3 days) and cytoplasmic (C) and nuclear (N) fractions were immunoblotted with b-catenin antibody. Normal melanocytes were studied in parallel. C/N ratios (determined by densitometric scanning) were obtained for three independent experiments and results are expressed as averages7s.e.m. In melanocytes, b-catenin was primarily cytoplasmic (C/N ¼ 10.270.51) whereas nuclear accumulation was evident in untreated melanoma cells (C/N ¼ 0.3670.04). Dox caused a timedependent increase in the C/N ratio (5.270.42 on day 3 post-treatment) (Figure 6a ). Re-probing of the stripped blots with H11/HspB8 antibody confirmed that it is strictly cytoplasmic (Figure 6b ), and fraction crosscontamination was excluded by further re-probing of the blots with antibodies to tubulin (cytoplasmic marker) and lamin B (nuclear marker) (Figure 6c ).
The data indicate that H11/HspB8 overload interferes with b-catenin nuclear accumulation.
b-Catenin is phosphorylated by activated TAK1 Two series of experiments were conducted to examine whether reduced nuclear accumulation of b-catenin in Dox-treated melanoma cells is related to TAK1 activation. Reciprocal pull-down assays indicated that the H11/HspB8, TAK1 and b-catenin antibodies pulled down their respective cognate proteins from untreated cells and preimmune IgG was negative. By contrast, in Dox-treated cells, both the H11/HspB8 and b-catenin antibodies pulled down TAK1, and all three proteins were pulled down by TAK1 antibody. H11/HspB8 and b-catenin did not co-immunoprecipitate unless pTAK1 was present, suggesting that b-catenin complexed to TAK1 activated by binding H11/HspB8. Indeed, immunoblotting of the anti-TAK1 precipitates with TAK1 antibody revealed the presence of pTAK1 in the Dox-treated, but not untreated cells (Figure 7a ).
In a second series of experiments, the cells were transfected with the dominant-negative TAK1 mutant K63W (Diao et al., 2005) (or the empty vector) and, 24 h later, they were treated (or not) with Dox (2 days), labeled with [ Overload of the heat-shock protein B Li et al untreated cells were negative (Figure 7b ). These findings are not an artifact owing to improper protein levels, because the levels of b-catenin were virtually identical in all the precipitates (Figure 7b ). The data indicate that TAK1 activation is involved in b-catenin phosphorylation.
Dox inhibits MITF and CDK2 expression and causes growth arrest
Having seen that Dox interferes with the nuclear accumulation of b-catenin, we wanted to know whether Overload of the heat-shock protein B Li et al this causes growth arrest through downregulation of the b-catenin transcriptional target MITF and the MITF target CDK2, both of which are required for melanoma cell proliferation (Widlund et al., 2002; Du et al., 2004) . Dox caused a time-dependent decrease in the levels of MITF (Figure 8a ) and CDK2 (Figure 8b ). It was accompanied by an increased proportion of cells in G1, and particularly in G2, and a decrease in the S-phase population, when compared to non-treated cells (Figure 8c ). The data suggest that H11 overload causes cell cycle arrest at G1 and G2, likely related to the function of CDK2 in both the G1/S and G2/M transitions of the cell cycle (Chae et al., 2004) .
TAK1 activation is required for H11/HspB8-mediated apoptosis To examine whether TAK1 activation is required for apoptosis, the H11/HspB8-positive melanoma cells were transfected with Flag-tagged K63W or control vector, treated with Dox and immunoblotted with caspase-3 antibody. Procaspase-3 was decreased by Dox (indicative of activation) and restored to basal levels by transfection with K63W, but not the control vector, although Flag was expressed equally well for both constructs (Figure 9a ). The results of three independent experiments (expressed as fold decrease7s.e.m.) indicate that Dox caused a three to fourfold decrease in procaspase-3 levels, which was not seen in K63W-transfected cells (Figure 9b ). The data indicate that TAK1 activation is required for caspase activation (apoptosis).
H11/HspB8-induced apoptosis is through TAK1-activated p38MAPK
To identify the TAK1-regulated pathways associated with Dox-induced apoptosis, the H11/HspB8-transfected melanoma cells were treated with Dox and immunoblotted with antibodies to phosphorylated (activated) p38MAPK (P-p38MAPK) or JNK (P-JNK) using antibodies to total p38MAPK and JNK as control. Pp38MAPK levels were increased on days 1 and 2 posttreatment, concomitant with caspase activation. The levels of P-JNK were not increased until day 3 posttreatment, when apoptosis was already maximal ( Figure  10a ). We conclude that apoptosis is p38MAPK dependent, because the p38MAPK inhibitor SB20350 blocked caspase activation (Figure 10b ) and restored TUNEL to its basal levels (Figure 10c ), whereas these were not altered by the JNK-specific inhibitor SP600125. The % TUNEL þ cells in SB203580-treated cells was similar to that seen in cells treated with the pan-caspase inhibitor Z-VAD-fmk, and was not further reduced by treatment with SB203580 þ Z-VAD-fmk (Figure 10c ).
Discussion
Melanoma is an aggressive cancer with increasing incidence and a growing lifetime risk (Margolin, 2004) that is intrinsically resistant to chemotherapy and apoptosis (Fink et 
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Apoptosis-based molecular therapies are desirable, but the identification of relevant gene target(s) is a major clinical challenge. The salient feature of our presented data is the finding that H11/HspB8 overload triggers apoptosis in melanoma, but not normal melanocytes, through TAK1 activation. Recent interest has focused on de-methylation as a platform for cancer therapy. A remarkably limited number of genes are upregulated by de-methylation (0.67% of 25 940 screened by microarray (Karpf et al., 2004) ). CDKN2A, APAF-1, TIMP3, GAGED2, MAGE-1 and RARB are methylated in melanoma, but their relationship to apoptosis is unclear (Soengas et al., 2001; Zendman et al., 2002; van der Velden et al., 2003; Furuta et al., 2004) . Aza-C sensitized a melanoma line to interferon-induced apoptosis (Reu et al., 2006) and DAC upregulated TSPY and suppressed the growth of two derivatives from another line (Gallagher et al., 2005) . The role of TSPY in independently established melanoma lines, the contribution of the other 65 upregulated genes and the mechanism of growth inhibition are still unresolved.
We found that Aza-C induced H11/HspB8 overload and caused cell death in 5/9 (55%) examined melanoma cultures, including two freshly isolated ones. Death was due to apoptosis caused by H11/HspB8 overload as evidenced by TUNEL inhibition with H11/HspB8 aODN, but not sODN. Apoptosis was also induced by Dox in melanoma cells stably transfected with Tet-regulated H11/HspB8, supporting the conclusion that it was mediated by H11/HspB8 overload. H11/ HspB8 did not have apoptotic activity in melanocytes. Preliminary data suggest that in these cells, as in cardiac myocytes (Hase et al., 2005) , H11/HspB8 protects from stress-induced apoptosis (unpublished). Although genes involved in cell fate determination (viz. Ras and TGF-b (Wakefield and Roberts, 2002; Cox and Der, 2003) ) have cell type and stimulus-specific pro-and antiapoptotic activities through distinct protein-protein interactions, this is a novel paradigm for an Hsp.
The Tet-inducible system was used to examine the mechanism of H11/HspB8-mediated apoptosis. We used A2058 and SKMEL2 cells to examine whether H11/ HspB8 can override the effects of the respective activating mutations in B-Raf or Ras. In both lines, Dox-induced H11/HspB8 overload caused growth arrest followed by apoptosis, as determined by activation of caspases-9 and -3 (intrinsic pathway) and DNA fragmentation (TUNEL þ cells). Apoptosis was not caused by deleterious effects of Dox on Hsp70 and Hsp27, which are antiapoptotic (Ciocca and Calderwood, 2005) , because these are expressed equally well in untreated and Dox-treated cells. Also, interaction of H11/HspB8 with Hsp27 (Sun et al., 2004) was not seen in pull-down assays of melanoma cells (Smith et al., 2000) and the bulk of the two proteins did not colocalize in sucrose gradient fractionation of extracts from Doxtreated melanoma cultures (Supplementary Figure 3) . Apoptosis is through TAK1 activation, because: (i) TAK1 bound H11/HspB8 and was phosphorylated in Dox-treated, but not untreated cells, (ii) the TAK1 kinase substrate MKK6 was phosphorylated in Doxtreated, but not untreated, cells, (iii) TAK1 did not bind the H11/HspB8 mutant W51C, which is dominant negative for apoptosis (Gober et al., 2003) and (iv) caspase activation was inhibited by the dominantnegative TAK1 mutant K63W.
In Dox-treated, but not untreated, melanoma cells, TAK1 bound b-catenin and was involved in its phosphorylation as evidenced by phosphorylation inhibition with the dominant-negative TAK1 mutant K63W and TAK1-specific aODN (data not shown). To the extent of our knowledge, this is the first report that TAK1 is involved in b-Catenin phosphorylation. b-catenin is phosphorylated by GSK-3b (on Tyrosine residues), or by cyclin-dependent CDK2 (on Ser33, Ser37, Thr41 and Ser45) promoting its proteosomal degradation (Park et al., 2004) . However, GSK-3b was not activated in Dox-treated melanoma cells (unpublished) and Dox did not reduce the levels of phosphorylated b-catenin, suggesting that TAK1-mediated Overload of the heat-shock protein B Li et al phosphorylation does not cause protein degradation and is likely to involve distinct serine-threonine residues. Its outcome appears to be reduced nuclear accumulation and inhibition of the b-catenin transcriptional activity, as evidenced by decreased levels of MITF in Doxtreated, as compared to untreated cells. Although final conclusions relating to the effect of H11/HspB8 overload on b-catenin transcriptional activity must await the results of ongoing studies of TCF/LEF1-luciferase reporter gene plasmids, our data indicate that the MITF target CDK2 was also inhibited in Dox-treated cells. Because CDK2 functions in the G1/S and G2/M transitions (Chae et al., 2004) , its inhibition is likely to be responsible for the growth arrest observed in the Dox-treated cells in G1, and particularly G2.
Apoptotic cells are predominantly derived from G2 arrested populations (Perez-Stable, 2006) . Our data do not address this question, but suggest that b-catenin is not directly involved in Dox-induced apoptosis, because both caspase activation and TUNEL were completely inhibited by the p38MAPK inhibitor, SB23058. Indeed, p38MAPK was activated in Dox-treated, but not untreated, cells, and SB203580 was as effective as the caspase inhibitor Z-VAD-fmk, in inhibiting Doxinduced activation of caspase-3. Although JNK was also activated in Dox-treated cells, caspase activation and TUNEL were not inhibited by the JNK inhibitor SP600125. This is consistent with previous reports that TAK1 activated JNK and p38MAPK can play different roles in the regulation of signal-mediated gene expression/function and activated p38MAPK suppresses the prosurvival nuclear factor-kappa B (NFkB), which can also be activated by TAK1 (Ivanov et al., 2001) . The mechanism of growth arrest/apoptosis induced by H11/HspB8 overload in melanoma cells is schematically represented in Figure 11 .
Melanoma-specific apoptosis by de-methylationinduced overload of the endogenous H11/HspB8 is a promising therapeutic platform, with TAK1, p38MAPK and b-catenin as potential targets for future H11/ HspB8-based therapies. Ongoing studies are using a PK-negative H11/HspB8 mutant to examine whether TAK1 is directly or indirectly phosphorylated by H11/ HspB8 kinase (Smith et al., 2000) , and considering the alternative possibility that H11/HspB8 facilitates TAK1 autophosphorylation, which is required for kinase activation by an intramolecular mechanism, potentially involving TAB proteins (Kishimoto et al., 2000) .
Materials and methods
Cells SK-MEL-2, SK-MEL-28, SKMEL-31 (human melanoma) and HEK293 were cultured in Eagle's minimal essential medium (EMEM) with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 0.1 mM non-essential amino acids. For SKMEL28, 4.5 g/l glucose, 1500 mg/ml sodium bicarbonate and 4 mM glutamine were added. Similarly, supplemented Dulbecco's modified Eagle's medium was used for melanoma cells A375 and A2058, and McCoy's 5A for melanoma cells G361 and HT144. HEK293 stably transfected with the H11 mutant W51C (TAG51) were described (Gober et al., 2003) . LM and MR were the gift of Dr Joseph Sinkovics (University of South Florida, USA). They were freshly established from metastatic melanomas and cultured in Roswell Park Memorial Institute 1640 with 10% FBS. Melanocyte cultures NM1 and NM2 (Cascade Biologicals, Portland, OR, USA) were passaged twice in medium 154 with HMGS, as per the manufacturer's instructions.
Antibodies and chemical reagents H11/HspB8 antibody H11-181 was described (Smith et al., 2000) . Antibodies M-579 (TAK-1), H-102 (b-catenin), C-20 (p38MAPK), C-11 (actin), H-50 (MITF), H277 (caspase-3), H-170 (caspase-9), FL (JNK1, p46, JNK2 p54 and JNK3), Overload of the heat-shock protein B Li et al N18 (lamin A/C), H235 (b-tubulin), M2 (CDK2) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to P-p38MAPK and P-JNK1/2 were from Cell Signaling (Beverly, MA, USA) and Promega (Madison, WI, USA), respectively. 5-Aza 2 0 -deoxycytidine (Aza-C), Dox and SP600125 were from Sigma Chemicals (St Louis, MO, USA), SB203580 and benzyloxcarbonyl-Val-Ala-Asp-fluormethyl ketone (z-VAD-fmk) from Calbiochem (La Jolla, CA, USA) and G418 and hygromycin from Invitrogen (Carlsbad, CA, USA).
Antisense oligonucleotides
The sequence and specificity of the phosphorothioate ODNs complementary to the H11/HspB8 translation initiation site (antisense ODN (aODN)) or sense ODN (sODN) and their use (30 mM; 4 days; 371C) were described (Smith et al., 2000; Gober et al., 2003) .
Plasmids and transfection
The W51C expression vector was described (Gober et al., 2003) . The FLAG-tagged TAK1 dominant-negative mutant K63W is the gift of Dr Chen Wang (University of Texas Southwestern Medical Center, TX, USA). K63W has a point mutation in the ATP-binding site and is kinase negative (Diao et al., 2005) . The control vector was FLAG-tagged HSV-1 UL17 and the empty expression vector p3xFLAG-CMV-10 (pFLAG) was from Sigma. Transient transfection was with 5 mg of DNA and Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as per the manufacturer's instructions.
Tet-inducible H11/HspB8 retrovirus vector and cell infection H11 DNA (0.6kb) was obtained by EcoR1/XbaI digestion of p3XFlag-cytomegalovirus-H11/HspB8 (Smith et al., 2000) . The Xba site was blunt ended and the fragment ligated into the EcoRI/SmaI site of pIRES2-EGFP vector (Clontech, Mountain View, CA, USA). A fragment containing H11/ HspB8-IRES-EGFP was isolated by EcoR1/NotI digestion, blunt ended and ligated into the HpaI site of the pRev-TRE retroviral vector, in which the mouse mammary tumor virus promoter drives a hygromycin resistance gene and the Tetsensitive promoter (Tet response element upstream of minimal CMV IE promoter) drives H11/HspB8. To generate retroviruses, the PT57 packaging cell line was transfected with pRevTet-On (contains G418 resistance cassette) or pRevTRE-H11/HspB8 and Lipofectamine 2000. Virus titers were assayed as per the manufacturer's instructions. Melanoma cells were infected with the Tet-On retrovirus at a multiplicity of infection (moi) of 50. Clones were selected with G418 (1 mg/ ml), infected with the TRE-H11/HspB8 retrovirus (moi ¼ 50) and selected with 800 mg/ml hygromycin. H11/HspB8 overload was induced with doxycycline (Dox; 2 mg/ml).
Cellular fractionation
Cells were resuspended in 50mM Tris-HCl buffer (pH 8.0) with 50 mM NaCl, 1% NP-40, 1 mM dithiothreitol (DTT) and protease inhibitors (Sigma, St Louis, MO, USA), incubated on ice 5 min and centrifuged (7000 g; 1 min). The supernatant is the cytoplasmic fraction. The nuclear pellet was resuspended in the same buffer but with 450 mM NaCl (10 min; 41C) and sonicated until in solution. The fractions were centrifuged (16 000 g; 30 min) before use.
FACS and cell cycle distribution
Low-density cultures (2-5 Â 10 5 cells/T75 flask) were trypsinized, the cells were fixed (70% ethanol; 41C; 12 h), resuspended in phosphate-buffered saline (PBS) with 1 mg/ml RNase (RT, 30 min) and stained with propidium iodide (Sigma, 20 mg/ml). Cell suspensions were filtered through a 40 mm filter and analysed for the cell cycle profile with the fluorescence activated cell sorting (FACS) Calibur flow cytometry system (BD, Biosciences, Franklin Lakes, NJ, USA) (Wang et al., 2006) .
Radiolabeling, immunoprecipitation and immunoblotting
Cells incubated (2 h; 371C) in phosphate-free EMEM with 10% dialyszed FBS were labeled (4 h) with [
32 P]-orthophosphate (250-500 mC/ml; Perkin Elmer Life and Analytical Sciences, Wellesley, MA, USA) and processed for immunoprecipitation and immunoblotting, as described (Smith et al., 2000; Gober et al., 2003) .
Immunocomplex protein kinase (PK) assays
Immunocomplex PK assays were as described (Kishimoto et al., 2000; Smith et al., 2000) using MKK6 (1 mg; Upstate Biotechnology, Lake Placid NY, USA) as the TAK1 kinase substrate and 10 mCi [ 32 P]-ATP (3000C/mM; Perkin Elmer).
TUNEL and immunofluorescence TUNEL was assayed with the in situ cell death detection kit (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instructions. Cells were counted in five randomly chosen microscopic fields (at least 250 cells) and results expressed as % TUNEL þ cells7s.e.m. For double immunofluorescence, cells were fixed with 4% paraformaldehyde (RT; 1 h), permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate (41C; 2 min) and incubated with terminal deoxynucleotidyltranferase and FITC-conjugated dUTPs (RT; 1 h). They were washed in PBS, blocked with 5% bovine serum albumin and 5% normal goat serum (RT; 1 h), and incubated with H11/HspB8 antibody (41C; 12 h) and Texas Red conjugated secondary antibody (RT; 1 h). Slides were mounted in VectaShield with DAPI (Vector) and visualized with a Nikon E4100 fluorescent microscope utilizing FITC (330-380nM), Texas Red (540-580 nM) and UV (for DAPI) (465-495 nM) cubes.
